Plain-English translation of NCT07563699 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new formulation of semaglutide — a medication that helps lower blood sugar, support weight loss, and reduce heart disease risk — designed to be injected once a month instead of once a week. Researchers want to find the safest and most effective dose of this new monthly version in adults with type 2 diabetes who are already doing well on the current weekly injection.
While the current semaglutide injections work well for many people, they require a weekly commitment. This trial exists to see if a new monthly version can provide the same benefits while making treatment easier and helping people stick with their diabetes medication.
You likely qualify if…
You likely don't qualify if…
You would receive monthly injections of the test medication at increasing doses across four small groups of participants. The study starts with the lowest dose and only moves to a higher dose after researchers confirm the previous dose is safe. Throughout the study, you'll have regular visits to check your blood sugar, weight, kidney and liver function, and any side effects you may experience. The entire study takes place at a research center in Tel Aviv, Israel.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
Israel